ALGERNON PHARMACEUT. A Market Cap ($740.91K)
Market Cap & Net Worth: ALGERNON PHARMACEUT. A (AGW0)
ALGERNON PHARMACEUT. A market cap. ALGERNON PHARMACEUT. A (F:AGW0) has a market capitalization of $740.91K (€633.74K) as of November 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #30848 globally and #2702 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ALGERNON PHARMACEUT. A's stock price €0.02 by its total outstanding shares 34256179 (34.26 Million).
ALGERNON PHARMACEUT. A Market Cap History (2016–2025)
ALGERNON PHARMACEUT. A market cap history from 2016 to 2025. Data shows change from $258.32 Million to $740.91K (-49.74% CAGR). Check latest ALGERNON PHARMACEUT. A stock price today for real-time trading data and today's change.
ALGERNON PHARMACEUT. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ALGERNON PHARMACEUT. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of AGW0 by Market Capitalization
Companies near ALGERNON PHARMACEUT. A in the global market cap rankings as of November 3, 2026.
Key companies related to ALGERNON PHARMACEUT. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of ALGERNON PHARMACEUT. A (2016–2025)
Market capitalization of ALGERNON PHARMACEUT. A from 2016 to today. Between 2016 and today, ALGERNON PHARMACEUT. A's market cap moved from $258.32 Million to $ 740.91K, with a yearly change of -49.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €740.91K | -7.50% |
| 2024 | €800.98K | -35.48% |
| 2023 | €1.24 Million | -92.00% |
| 2022 | €15.52 Million | -45.04% |
| 2021 | €28.23 Million | -78.80% |
| 2020 | €133.16 Million | +421.57% |
| 2019 | €25.53 Million | -61.94% |
| 2018 | €67.08 Million | -81.18% |
| 2017 | €356.44 Million | +37.98% |
| 2016 | €258.32 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 16th, 2026 the market cap of ALGERNON PHARMACEUT. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $740.91K USD |
| MoneyControl | $740.91K USD |
| MarketWatch | $740.91K USD |
| marketcap.company | $740.91K USD |
| Reuters | $740.91K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ALGERNON PHARMACEUT. A
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. It pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosi… Read more